메뉴 건너뛰기
Cytokine and Growth Factor Reviews
Volumn 26, Issue 2, 2015, Pages 249-261
Pharmacogenomics of interferon-β in multiple sclerosis: What has been accomplished and how can we ensure future progress?
Author keywords

Interferon ; Multiple sclerosis; Neutralizing antibodies; Pharmacogenomics; Responders
Indexed keywords

ADENOSINE DEAMINASE; BETA1A INTERFERON; CALPASTATIN; CHEMOKINE RECEPTOR CCR5; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLATIRAMER; GLYPICAN; HLA DRB1 ANTIGEN; HYALURONIC ACID; INTERFERON BETA SERINE; INTERFERON REGULATORY FACTOR 5; INTERFERON REGULATORY FACTOR 6; IONOTROPIC RECEPTOR; JANUS KINASE 2; MEMBRANE COFACTOR PROTEIN; MYXOVIRUS RESISTANCE PROTEIN A; NATALIZUMAB; NEUTRALIZING ANTIBODY; PROTEIN SERINE THREONINE KINASE; STEROIDOGENIC ACUTE REGULATORY PROTEIN; TERIFLUNOMIDE; ZINC FINGER PROTEIN; BETA INTERFERON; INTERFERON REGULATORY FACTOR; IRF5 PROTEIN, HUMAN;
EID: 84926526723     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2014.10.008     Document Type: Review
Times cited : (8)
References (119)
  • 1
    • 33644607018 scopus 로고    scopus 로고
    • Multiple sclerosis: the plaque and its pathogenesis
    • Frohman E.M., Racke M.K., Raine C.S. Multiple sclerosis: the plaque and its pathogenesis. N Engl J Med 2006, 354:942-955. http://www.ncbi.nlm.nih.gov/pubmed/16510748.
    • (2006) N Engl J Med , vol.354 , pp. 942-955
    • Frohman, E.M.1    Racke, M.K.2    Raine, C.S.3
  • 2
    • 0029730733 scopus 로고    scopus 로고
    • Accumulation of hypointense lesions ('black holes') on T1 spin-echo MRI correlates with disease progression in multiple sclerosis
    • Truyen L., van Waesberghe J.H., van Walderveen M.A., van Oosten B.W., Polman C.H., Hommes O.R., et al. Accumulation of hypointense lesions ('black holes') on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology 1996, 47:1469-1476. http://www.ncbi.nlm.nih.gov/pubmed/8960729.
    • (1996) Neurology , vol.47 , pp. 1469-1476
    • Truyen, L.1    van Waesberghe, J.H.2    van Walderveen, M.A.3    van Oosten, B.W.4    Polman, C.H.5    Hommes, O.R.6
  • 3
    • 79952501096 scopus 로고    scopus 로고
    • Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
    • Polman C.H., Reingold S.C., Banwell B., Clanet M., Cohen J.A., Filippi M., et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011, 69:292-302. http://www.ncbi.nlm.nih.gov/pubmed/21387374.
    • (2011) Ann Neurol , vol.69 , pp. 292-302
    • Polman, C.H.1    Reingold, S.C.2    Banwell, B.3    Clanet, M.4    Cohen, J.A.5    Filippi, M.6
  • 4
    • 77953750773 scopus 로고    scopus 로고
    • New perspectives in the natural history of multiple sclerosis
    • Tremlett H., Zhao Y., Rieckmann P., Hutchinson M. New perspectives in the natural history of multiple sclerosis. Neurology 2010, 74:2004-2015. http://www.ncbi.nlm.nih.gov/pubmed/20548045.
    • (2010) Neurology , vol.74 , pp. 2004-2015
    • Tremlett, H.1    Zhao, Y.2    Rieckmann, P.3    Hutchinson, M.4
  • 5
    • 76649105437 scopus 로고    scopus 로고
    • Disability and survival of multiple sclerosis in Saskatoon, Saskatchewan
    • Hader W.J. Disability and survival of multiple sclerosis in Saskatoon, Saskatchewan. Can J Neurol Sci 2010, 37:28-35. http://www.ncbi.nlm.nih.gov/pubmed/20169770.
    • (2010) Can J Neurol Sci , vol.37 , pp. 28-35
    • Hader, W.J.1
  • 7
    • 0021035886 scopus 로고
    • Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)
    • Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-1452. http://www.ncbi.nlm.nih.gov/pubmed/6685237.
    • (1983) Neurology , vol.33 , pp. 1444-1452
    • Kurtzke, J.F.1
  • 8
    • 0037029424 scopus 로고    scopus 로고
    • Multiple sclerosis
    • Compston A., Coles A. Multiple sclerosis. Lancet 2002, 359:1221-1231. http://www.ncbi.nlm.nih.gov/pubmed/11955556.
    • (2002) Lancet , vol.359 , pp. 1221-1231
    • Compston, A.1    Coles, A.2
  • 9
    • 45549092100 scopus 로고    scopus 로고
    • The genetics of multiple sclerosis: SNPs to pathways to pathogenesis
    • Oksenberg J.R., Baranzini S.E., Sawcer S., Hauser S.L. The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat Rev Genet 2008, 9:516-526. http://www.ncbi.nlm.nih.gov/pubmed/18542080.
    • (2008) Nat Rev Genet , vol.9 , pp. 516-526
    • Oksenberg, J.R.1    Baranzini, S.E.2    Sawcer, S.3    Hauser, S.L.4
  • 10
    • 84876491216 scopus 로고    scopus 로고
    • Future MS care: a consensus statement of the MS in the 21st century steering group
    • Rieckmann P., Boyko A., Centonze D., Coles A., Elovaara I., Havrdová E., et al. Future MS care: a consensus statement of the MS in the 21st century steering group. J Neurol 2013, 260:462-469. http://www.ncbi.nlm.nih.gov/pubmed/22936203.
    • (2013) J Neurol , vol.260 , pp. 462-469
    • Rieckmann, P.1    Boyko, A.2    Centonze, D.3    Coles, A.4    Elovaara, I.5    Havrdová, E.6
  • 11
    • 32044463386 scopus 로고    scopus 로고
    • Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients
    • Río J., Nos C., Tintoré M., Téllez N., Galán I., Pelayo R., et al. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol 2006, 59:344-352. http://www.ncbi.nlm.nih.gov/pubmed/16437558.
    • (2006) Ann Neurol , vol.59 , pp. 344-352
    • Río, J.1    Nos, C.2    Tintoré, M.3    Téllez, N.4    Galán, I.5    Pelayo, R.6
  • 12
    • 84912012860 scopus 로고    scopus 로고
    • Current developments in pharmacogenomics of multiple sclerosis
    • Carlson R.J., Doucette J.R., Nazarali A.J. Current developments in pharmacogenomics of multiple sclerosis. Cell Mol Neurobiol 2014, 34(8):1081-1085.
    • (2014) Cell Mol Neurobiol , vol.34 , Issue.8 , pp. 1081-1085
    • Carlson, R.J.1    Doucette, J.R.2    Nazarali, A.J.3
  • 13
    • 84888006454 scopus 로고    scopus 로고
    • Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature
    • Mahurkar S., Suppiah V., O'Doherty C. Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature. Autoimmun Rev 2014, 13:178-186. http://www.ncbi.nlm.nih.gov/pubmed/24189284.
    • (2014) Autoimmun Rev , vol.13 , pp. 178-186
    • Mahurkar, S.1    Suppiah, V.2    O'Doherty, C.3
  • 14
    • 40849094272 scopus 로고    scopus 로고
    • Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis
    • Byun E., Caillier S.J., Montalban X., Villoslada P., Fernández O., Brassat D., et al. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. Arch Neurol 2008, 65:337-344. http://www.ncbi.nlm.nih.gov/pubmed/18195134.
    • (2008) Arch Neurol , vol.65 , pp. 337-344
    • Byun, E.1    Caillier, S.J.2    Montalban, X.3    Villoslada, P.4    Fernández, O.5    Brassat, D.6
  • 16
    • 72649106903 scopus 로고    scopus 로고
    • A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis
    • Comabella M., Lünemann J.D., Río J., Sánchez A., López C., Julià E., et al. A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain 2009, 132:3353-3365. http://www.ncbi.nlm.nih.gov/pubmed/19741051.
    • (2009) Brain , vol.132 , pp. 3353-3365
    • Comabella, M.1    Lünemann, J.D.2    Río, J.3    Sánchez, A.4    López, C.5    Julià, E.6
  • 17
    • 44849128066 scopus 로고    scopus 로고
    • Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients
    • Van Baarsen L.G., Vosslamber S., Tijssen M., Baggen J.M., van der Voort L.F., Killestein J., et al. Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. PLoS ONE 2008, 3:e1927. http://www.ncbi.nlm.nih.gov/pubmed/18382694, 10.1371/journal.pone.0001927.
    • (2008) PLoS ONE , vol.3 , pp. e1927
    • Van Baarsen, L.G.1    Vosslamber, S.2    Tijssen, M.3    Baggen, J.M.4    van der Voort, L.F.5    Killestein, J.6
  • 18
    • 84881300895 scopus 로고    scopus 로고
    • Relevance of the type I interferon signature in multiple sclerosis towards a personalized medicine approach for interferon-beta therapy
    • Verweij C.L., Vosslamber S. Relevance of the type I interferon signature in multiple sclerosis towards a personalized medicine approach for interferon-beta therapy. Discov Med 2013, 15:51-60. http://www.ncbi.nlm.nih.gov/pubmed/23375014.
    • (2013) Discov Med , vol.15 , pp. 51-60
    • Verweij, C.L.1    Vosslamber, S.2
  • 19
    • 77955600004 scopus 로고    scopus 로고
    • IFN-beta pharmacogenomics in multiple sclerosis
    • Vandenbroeck K., Urcelay E., Comabella M. IFN-beta pharmacogenomics in multiple sclerosis. Pharmacogenomics 2010, 11:1137-1148. http://www.ncbi.nlm.nih.gov/pubmed/20712530.
    • (2010) Pharmacogenomics , vol.11 , pp. 1137-1148
    • Vandenbroeck, K.1    Urcelay, E.2    Comabella, M.3
  • 20
    • 84859913275 scopus 로고    scopus 로고
    • Single nucleotide polymorphisms in multiple sclerosis: disease susceptibility and treatment response biomarkers
    • Pravica V., Popadic D., Savic E., Markovic M., Drulovic J., Mostarica-Stojkovic M. Single nucleotide polymorphisms in multiple sclerosis: disease susceptibility and treatment response biomarkers. Immunol Res 2012, 52:42-52. http://www.ncbi.nlm.nih.gov/pubmed/22392049.
    • (2012) Immunol Res , vol.52 , pp. 42-52
    • Pravica, V.1    Popadic, D.2    Savic, E.3    Markovic, M.4    Drulovic, J.5    Mostarica-Stojkovic, M.6
  • 21
    • 68549085471 scopus 로고    scopus 로고
    • Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis
    • Comabella M., Craig D.W., Morcillo-Suárez C., Río J., Navarro A., Fernández M., et al. Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis. Arch Neurol 2009, 66:972-978. http://www.ncbi.nlm.nih.gov/pubmed/19667218.
    • (2009) Arch Neurol , vol.66 , pp. 972-978
    • Comabella, M.1    Craig, D.W.2    Morcillo-Suárez, C.3    Río, J.4    Navarro, A.5    Fernández, M.6
  • 22
    • 58949099391 scopus 로고    scopus 로고
    • Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis
    • Baranzini S.E., Wang J., Gibson R.A., Galwey N., Naegelin Y., Barkhof F., et al. Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet 2009, 18:767-778. http://www.ncbi.nlm.nih.gov/pubmed/19010793.
    • (2009) Hum Mol Genet , vol.18 , pp. 767-778
    • Baranzini, S.E.1    Wang, J.2    Gibson, R.A.3    Galwey, N.4    Naegelin, Y.5    Barkhof, F.6
  • 23
    • 0642278522 scopus 로고    scopus 로고
    • Pharmacogenomic analysis of interferon receptor polymorphisms in multiple sclerosis
    • Sriram U., Barcellos L.F., Villoslada P., Rio J., Baranzini S.E., Caillier S., et al. Pharmacogenomic analysis of interferon receptor polymorphisms in multiple sclerosis. Genes Immun 2003, 4:147-152. http://www.ncbi.nlm.nih.gov/pubmed/12618863.
    • (2003) Genes Immun , vol.4 , pp. 147-152
    • Sriram, U.1    Barcellos, L.F.2    Villoslada, P.3    Rio, J.4    Baranzini, S.E.5    Caillier, S.6
  • 25
    • 28844476586 scopus 로고    scopus 로고
    • Pharmacogenomics of responsiveness to interferon IFN-beta treatment in multiple sclerosis: a genetic screen of 100 type I interferon-inducible genes
    • Cunningham S., Graham C., Hutchinson M., Droogan A., O'Rourke K., Patterson C., et al. Pharmacogenomics of responsiveness to interferon IFN-beta treatment in multiple sclerosis: a genetic screen of 100 type I interferon-inducible genes. Clin Pharmacol Ther 2005, 78:635-646. http://www.ncbi.nlm.nih.gov/pubmed/16338279.
    • (2005) Clin Pharmacol Ther , vol.78 , pp. 635-646
    • Cunningham, S.1    Graham, C.2    Hutchinson, M.3    Droogan, A.4    O'Rourke, K.5    Patterson, C.6
  • 26
    • 34250205988 scopus 로고    scopus 로고
    • Pharmacogenomics of type I interferon therapy: a survey of response-modifying genes
    • O'Doherty C., Villoslada P., Vandenbroeck K. Pharmacogenomics of type I interferon therapy: a survey of response-modifying genes. Cytokine Growth Factor Rev 2007, 18:211-222. http://www.ncbi.nlm.nih.gov/pubmed/17540610.
    • (2007) Cytokine Growth Factor Rev , vol.18 , pp. 211-222
    • O'Doherty, C.1    Villoslada, P.2    Vandenbroeck, K.3
  • 27
    • 84861317353 scopus 로고    scopus 로고
    • Interferon regulatory factors: beyond the antiviral response and their link to the development of autoimmune pathology
    • Santana-de Anda K., Gómez-Martín D., Díaz-Zamudio M., Alcocer-Varela J. Interferon regulatory factors: beyond the antiviral response and their link to the development of autoimmune pathology. Autoimmun Rev 2011, 11:98-103. http://www.ncbi.nlm.nih.gov/pubmed/21872684.
    • (2011) Autoimmun Rev , vol.11 , pp. 98-103
    • Santana-de Anda, K.1    Gómez-Martín, D.2    Díaz-Zamudio, M.3    Alcocer-Varela, J.4
  • 28
    • 80052284686 scopus 로고    scopus 로고
    • Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of interferon-β therapy in multiple sclerosis
    • Vosslamber S., van der Voort L.F., van den Elskamp I.J., Heijmans R., Aubin C., Uitdehaag B.M.J., et al. Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of interferon-β therapy in multiple sclerosis. Genes Immun 2011, 12:466-472. http://www.ncbi.nlm.nih.gov/pubmed/21471993.
    • (2011) Genes Immun , vol.12 , pp. 466-472
    • Vosslamber, S.1    van der Voort, L.F.2    van den Elskamp, I.J.3    Heijmans, R.4    Aubin, C.5    Uitdehaag, B.M.J.6
  • 29
    • 78751649865 scopus 로고    scopus 로고
    • Validation of IRF5 as multiple sclerosis risk gene: putative role in interferon beta therapy and human herpes virus-6 infection
    • Vandenbroeck K., Alloza I., Swaminathan B., Antigüedad A., Otaegui D., Olascoaga J., et al. Validation of IRF5 as multiple sclerosis risk gene: putative role in interferon beta therapy and human herpes virus-6 infection. Genes Immun 2011, 12:40-45. http://www.ncbi.nlm.nih.gov/pubmed/20861862.
    • (2011) Genes Immun , vol.12 , pp. 40-45
    • Vandenbroeck, K.1    Alloza, I.2    Swaminathan, B.3    Antigüedad, A.4    Otaegui, D.5    Olascoaga, J.6
  • 30
    • 84925351744 scopus 로고    scopus 로고
    • Prediction of response to interferon therapy in multiple sclerosis
    • [Epub ahead of print]
    • Sellebjerg F., Søndergaard H.B., Koch-Henriksen N., Sørensen P.S., Oturai A.B. Prediction of response to interferon therapy in multiple sclerosis. Acta Neurol Scand 2014, (June). [Epub ahead of print]. http://www.ncbi.nlm.nih.gov/pubmed/24943672, 10.1111/ane.12269.
    • (2014) Acta Neurol Scand , Issue.JUNE
    • Sellebjerg, F.1    Søndergaard, H.B.2    Koch-Henriksen, N.3    Sørensen, P.S.4    Oturai, A.B.5
  • 31
    • 11944272254 scopus 로고
    • Quantitative methods in psychology: a power primer
    • Cohen J. Quantitative methods in psychology: a power primer. Psychol Bull 1992, 112:155-159.
    • (1992) Psychol Bull , vol.112 , pp. 155-159
    • Cohen, J.1
  • 32
    • 44949253948 scopus 로고    scopus 로고
    • Pharmacogenomics of the response to IFN-β in multiple sclerosis: ramifications from the first genome-wide screen
    • Vandenbroeck K., Matute C. Pharmacogenomics of the response to IFN-β in multiple sclerosis: ramifications from the first genome-wide screen. Pharmacogenomics 2008, 9:639-645. http://www.ncbi.nlm.nih.gov/pubmed/18466107.
    • (2008) Pharmacogenomics , vol.9 , pp. 639-645
    • Vandenbroeck, K.1    Matute, C.2
  • 33
    • 66849106883 scopus 로고    scopus 로고
    • United Europeans for development of pharmacogenomics in multiple sclerosis network
    • Vandenbroeck K., Comabella M., Tolosa E., Goertsches R., Brassat D., Hintzen R., et al. United Europeans for development of pharmacogenomics in multiple sclerosis network. Pharmacogenomics 2009, 10:885-894. http://www.ncbi.nlm.nih.gov/pubmed/19450134.
    • (2009) Pharmacogenomics , vol.10 , pp. 885-894
    • Vandenbroeck, K.1    Comabella, M.2    Tolosa, E.3    Goertsches, R.4    Brassat, D.5    Hintzen, R.6
  • 34
    • 80054889075 scopus 로고    scopus 로고
    • IL28B polymorphisms are not associated with the response to interferon-β in multiple sclerosis
    • Malhotra S., Morcillo-Suárez C., Brassat D., Goertsches R., Lechner-Scott J., Urcelay E., et al. IL28B polymorphisms are not associated with the response to interferon-β in multiple sclerosis. J Neuroimmunol 2011, 239:101-104. http://www.ncbi.nlm.nih.gov/pubmed/21889215.
    • (2011) J Neuroimmunol , vol.239 , pp. 101-104
    • Malhotra, S.1    Morcillo-Suárez, C.2    Brassat, D.3    Goertsches, R.4    Lechner-Scott, J.5    Urcelay, E.6
  • 35
    • 79953301944 scopus 로고    scopus 로고
    • Population structure and HLA DRB1 1501 in the response of subjects with multiple sclerosis to first-line treatments
    • Gross R., Healy B.C., Cepok S., Chitnis T., Khoury S.J., Hemmer B., et al. Population structure and HLA DRB1 1501 in the response of subjects with multiple sclerosis to first-line treatments. J Neuroimmunol 2011, 233:168-174. http://www.ncbi.nlm.nih.gov/pubmed/21115201.
    • (2011) J Neuroimmunol , vol.233 , pp. 168-174
    • Gross, R.1    Healy, B.C.2    Cepok, S.3    Chitnis, T.4    Khoury, S.J.5    Hemmer, B.6
  • 36
    • 84876911065 scopus 로고    scopus 로고
    • Candidate gene study of TRAIL and TRAIL receptors: association with response to interferon beta therapy in multiple sclerosis patients
    • López-Gómez C., Pino-Ángeles A., Órpez-Zafra T., Pinto-Medel M.J., Oliver-Martos B., Ortega-Pinazo J., et al. Candidate gene study of TRAIL and TRAIL receptors: association with response to interferon beta therapy in multiple sclerosis patients. PLOS ONE 2013, 8:e62540. http://www.ncbi.nlm.nih.gov/pubmed/23658636, 10.1371/journal.pone.0062540.
    • (2013) PLOS ONE , vol.8 , pp. e62540
    • López-Gómez, C.1    Pino-Ángeles, A.2    Órpez-Zafra, T.3    Pinto-Medel, M.J.4    Oliver-Martos, B.5    Ortega-Pinazo, J.6
  • 37
    • 84899796817 scopus 로고    scopus 로고
    • Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate
    • Kulakova O.G., Tsareva E.Y., Lvovs D., Favarov A.V., Boyko A.N., Favarova O.O. Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate. Pharmacogenomics 2014, 15:679-685. http://www.ncbi.nlm.nih.gov/pubmed/24798724.
    • (2014) Pharmacogenomics , vol.15 , pp. 679-685
    • Kulakova, O.G.1    Tsareva, E.Y.2    Lvovs, D.3    Favarov, A.V.4    Boyko, A.N.5    Favarova, O.O.6
  • 38
    • 79953803423 scopus 로고    scopus 로고
    • Determinants of interferon β efficacy in patients with multiple sclerosis
    • Killestein J., Polman C.H. Determinants of interferon β efficacy in patients with multiple sclerosis. Nat Rev Neurol 2011, 7:221-228. http://www.ncbi.nlm.nih.gov/pubmed/21364522.
    • (2011) Nat Rev Neurol , vol.7 , pp. 221-228
    • Killestein, J.1    Polman, C.H.2
  • 40
    • 77957333843 scopus 로고    scopus 로고
    • Single-nucleotide polymorphisms in response to interferon-beta therapy in multiple sclerosis
    • Vandenbroeck K., Comabella M. Single-nucleotide polymorphisms in response to interferon-beta therapy in multiple sclerosis. J Interferon Cytokine Res 2010, 30:727-732. http://www.ncbi.nlm.nih.gov/pubmed/20836710.
    • (2010) J Interferon Cytokine Res , vol.30 , pp. 727-732
    • Vandenbroeck, K.1    Comabella, M.2
  • 41
    • 70349745515 scopus 로고    scopus 로고
    • Predicting responders to therapies for multiple sclerosis
    • Río J., Comabella M., Montalban X. Predicting responders to therapies for multiple sclerosis. Nat Rev Neurol 2009, 5:553-560. http://www.ncbi.nlm.nih.gov/pubmed/19794514.
    • (2009) Nat Rev Neurol , vol.5 , pp. 553-560
    • Río, J.1    Comabella, M.2    Montalban, X.3
  • 42
    • 84883742251 scopus 로고    scopus 로고
    • Treatment optimization in MS: Canadian MS Working Group updated recommendations
    • Freedman M.S., Selchen D., Arnold D.L., Prat A., Banwell B., Yeung M., et al. Treatment optimization in MS: Canadian MS Working Group updated recommendations. Can J Neurol Sci 2013, 40:307-323. http://www.ncbi.nlm.nih.gov/pubmed/23603165.
    • (2013) Can J Neurol Sci , vol.40 , pp. 307-323
    • Freedman, M.S.1    Selchen, D.2    Arnold, D.L.3    Prat, A.4    Banwell, B.5    Yeung, M.6
  • 43
    • 20044396374 scopus 로고    scopus 로고
    • IL-10 promoter haplotype influence on interferon treatment response in multiple sclerosis
    • Wergeland S., Beiske A., Nyland H., Hovdal H., Jensen D., Larsen J.P., et al. IL-10 promoter haplotype influence on interferon treatment response in multiple sclerosis. Eur J Neurol 2005, 12:171-175. http://www.ncbi.nlm.nih.gov/pubmed/15693804.
    • (2005) Eur J Neurol , vol.12 , pp. 171-175
    • Wergeland, S.1    Beiske, A.2    Nyland, H.3    Hovdal, H.4    Jensen, D.5    Larsen, J.P.6
  • 44
    • 70349655565 scopus 로고    scopus 로고
    • The present efficacy of multiple sclerosis therapeutics: is the new 66% just the old 33%?
    • Klawiter E.C., Cross A.H., Naismith R.T. The present efficacy of multiple sclerosis therapeutics: is the new 66% just the old 33%?. Neurology 2009, 73:984-990. http://www.ncbi.nlm.nih.gov/pubmed/19770475.
    • (2009) Neurology , vol.73 , pp. 984-990
    • Klawiter, E.C.1    Cross, A.H.2    Naismith, R.T.3
  • 45
    • 84866423965 scopus 로고    scopus 로고
    • Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis
    • Gold R., Kappos L., Arnold D.L., Bar-Or A., Giovannoni G., Selmaj K., et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012, 367:1098-1107. http://www.ncbi.nlm.nih.gov/pubmed/22992073.
    • (2012) N Engl J Med , vol.367 , pp. 1098-1107
    • Gold, R.1    Kappos, L.2    Arnold, D.L.3    Bar-Or, A.4    Giovannoni, G.5    Selmaj, K.6
  • 46
    • 0027418515 scopus 로고
    • Interferon Beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial
    • The IFNB Multiple Sclerosis Study Group Interferon Beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993, 43:655-661. http://www.ncbi.nlm.nih.gov/pubmed/8469318.
    • (1993) Neurology , vol.43 , pp. 655-661
  • 47
    • 0032893876 scopus 로고    scopus 로고
    • Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies
    • Deisenhammer F., Reindl M., Harvey J., Gasse T., Dilitz E., Berger T. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 1999, 52:1239-1243. http://www.ncbi.nlm.nih.gov/pubmed/10214750.
    • (1999) Neurology , vol.52 , pp. 1239-1243
    • Deisenhammer, F.1    Reindl, M.2    Harvey, J.3    Gasse, T.4    Dilitz, E.5    Berger, T.6
  • 48
    • 0037172854 scopus 로고    scopus 로고
    • Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients
    • Vallittu A.-M., Halminen M., Peltoniemi J., Ilonen J., Julkunen I., Salmi A., et al. Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients. Neurology 2002, 58:1786-1790. http://www.ncbi.nlm.nih.gov/pubmed/12084878.
    • (2002) Neurology , vol.58 , pp. 1786-1790
    • Vallittu, A.-M.1    Halminen, M.2    Peltoniemi, J.3    Ilonen, J.4    Julkunen, I.5    Salmi, A.6
  • 49
    • 0031841745 scopus 로고    scopus 로고
    • Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis, multiple sclerosis collaborative research group (MSCRG)
    • Rudick R.A., Simonian N.A., Alam J.A., Campion M., Scaramucci J.O., Jones W., et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis, multiple sclerosis collaborative research group (MSCRG). Neurology 1998, 50:1266-1272. http://www.ncbi.nlm.nih.gov/pubmed/9595973.
    • (1998) Neurology , vol.50 , pp. 1266-1272
    • Rudick, R.A.1    Simonian, N.A.2    Alam, J.A.3    Campion, M.4    Scaramucci, J.O.5    Jones, W.6
  • 50
    • 0242658889 scopus 로고    scopus 로고
    • Anti-IFN BAb and NAb antibodies: a minireview
    • Bendtzen K. Anti-IFN BAb and NAb antibodies: a minireview. Neurology 2003, 61:S6-S10. http://www.ncbi.nlm.nih.gov/pubmed/14610102.
    • (2003) Neurology , vol.61 , pp. S6-S10
    • Bendtzen, K.1
  • 51
    • 77957352554 scopus 로고    scopus 로고
    • Critical review: assessment of interferon-β immunogenicity in multiple sclerosis
    • Bendtzen K. Critical review: assessment of interferon-β immunogenicity in multiple sclerosis. J Interferon Cytokine Res 2010, 30:759-766. http://www.ncbi.nlm.nih.gov/pubmed/20874253.
    • (2010) J Interferon Cytokine Res , vol.30 , pp. 759-766
    • Bendtzen, K.1
  • 52
    • 31644438194 scopus 로고    scopus 로고
    • Measuring and evaluating interferon β-induced antibodies in patients with multiple sclerosis
    • Ross C., Clemmesen K.M., Sørensen P.S., Koch-Henriksen N., Bendtzen K. Measuring and evaluating interferon β-induced antibodies in patients with multiple sclerosis. Mult Scler 2006, 12:39-46. http://www.ncbi.nlm.nih.gov/pubmed/16459718.
    • (2006) Mult Scler , vol.12 , pp. 39-46
    • Ross, C.1    Clemmesen, K.M.2    Sørensen, P.S.3    Koch-Henriksen, N.4    Bendtzen, K.5
  • 53
    • 84899114713 scopus 로고    scopus 로고
    • Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development
    • Hegen H., Millonig A., Bertolotto A., Comabella M., Giovanonni G., Guger M., et al. Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development. Mult Scler 2014, 20:577-587. http://www.ncbi.nlm.nih.gov/pubmed/24009164.
    • (2014) Mult Scler , vol.20 , pp. 577-587
    • Hegen, H.1    Millonig, A.2    Bertolotto, A.3    Comabella, M.4    Giovanonni, G.5    Guger, M.6
  • 54
    • 85027953762 scopus 로고    scopus 로고
    • Correlation between anti-interferon-β binding and neutralizing antibodies in interferon-β-treated multiple sclerosis patients
    • Jensen P.E.H., Sellebjerg F., Søndergaard H.B., Sørensen P.S. Correlation between anti-interferon-β binding and neutralizing antibodies in interferon-β-treated multiple sclerosis patients. Eur J Neurol 2012, 19:1311-1317. http://www.ncbi.nlm.nih.gov/pubmed/22564111.
    • (2012) Eur J Neurol , vol.19 , pp. 1311-1317
    • Jensen, P.E.H.1    Sellebjerg, F.2    Søndergaard, H.B.3    Sørensen, P.S.4
  • 55
    • 84879336715 scopus 로고    scopus 로고
    • Immunoglobulin G1 and immunoglobulin G4 antibodies in multiple sclerosis patients treated with IFNβ interact with the endogenous cytokine and activate complement
    • Sethu S., Govindappa K., Quinn P., Wadhwa M., Stebbings R., Boggild M., et al. Immunoglobulin G1 and immunoglobulin G4 antibodies in multiple sclerosis patients treated with IFNβ interact with the endogenous cytokine and activate complement. Clin Immunol 2013, 148:177-185. http://www.ncbi.nlm.nih.gov/pubmed/23770627.
    • (2013) Clin Immunol , vol.148 , pp. 177-185
    • Sethu, S.1    Govindappa, K.2    Quinn, P.3    Wadhwa, M.4    Stebbings, R.5    Boggild, M.6
  • 56
    • 0035012959 scopus 로고    scopus 로고
    • Study of binding and neutralising antibodies to interferon-beta in two groups of relapsing-remitting multiple sclerosis patients
    • Fernández O., Mayorga C., Luque G., Guerrero M., Guerrero R., Leyva L., et al. Study of binding and neutralising antibodies to interferon-beta in two groups of relapsing-remitting multiple sclerosis patients. J Neurol 2001, 248:383-388. http://www.ncbi.nlm.nih.gov/pubmed/11437159.
    • (2001) J Neurol , vol.248 , pp. 383-388
    • Fernández, O.1    Mayorga, C.2    Luque, G.3    Guerrero, M.4    Guerrero, R.5    Leyva, L.6
  • 57
    • 0036329631 scopus 로고    scopus 로고
    • Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory
    • Bertolotto A., Malucchi S., Sala A., Orefice G., Carrieri P.B., Capobianco M., et al. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. J Neurol Neurosurg Psychiatry 2002, 73:148-153. http://www.ncbi.nlm.nih.gov/pubmed/12122172.
    • (2002) J Neurol Neurosurg Psychiatry , vol.73 , pp. 148-153
    • Bertolotto, A.1    Malucchi, S.2    Sala, A.3    Orefice, G.4    Carrieri, P.B.5    Capobianco, M.6
  • 58
    • 0033763507 scopus 로고    scopus 로고
    • Immunogenicity of interferon-β in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group
    • Ross C., Clemmesen K.M., Svenson M., Sørensen P.S., Koch-Henriksen N., Skovgaard G.L., et al. Immunogenicity of interferon-β in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol 2000, 48:706-712. http://www.ncbi.nlm.nih.gov/pubmed/11079533.
    • (2000) Ann Neurol , vol.48 , pp. 706-712
    • Ross, C.1    Clemmesen, K.M.2    Svenson, M.3    Sørensen, P.S.4    Koch-Henriksen, N.5    Skovgaard, G.L.6
  • 59
    • 18344374867 scopus 로고    scopus 로고
    • Neutralizing and binding antibodies to IFN-beta: relative frequency in relapsing-remitting multiple sclerosis patients treated with different IFN-beta preparations
    • Scagnolari C., Bellomi F., Turriziani O., Bagnato F., Tomassini V., Lavolpe V., et al. Neutralizing and binding antibodies to IFN-beta: relative frequency in relapsing-remitting multiple sclerosis patients treated with different IFN-beta preparations. J Interferon Cytokine Res 2002, 22:207-213. http://www.ncbi.nlm.nih.gov/pubmed/11911803.
    • (2002) J Interferon Cytokine Res , vol.22 , pp. 207-213
    • Scagnolari, C.1    Bellomi, F.2    Turriziani, O.3    Bagnato, F.4    Tomassini, V.5    Lavolpe, V.6
  • 60
    • 0034455447 scopus 로고    scopus 로고
    • Neutralizing and binding anti-interferon-beta (IFN-beta) antibodies. A comparison between IFN-beta-1a and IFN-beta-1b treatment in multiple sclerosis
    • Kivisäkk P., Alm G.V., Fredrikson S., Link H. Neutralizing and binding anti-interferon-beta (IFN-beta) antibodies. A comparison between IFN-beta-1a and IFN-beta-1b treatment in multiple sclerosis. Eur J Neurol 2000, 7:27-34. http://www.ncbi.nlm.nih.gov/pubmed/10809912.
    • (2000) Eur J Neurol , vol.7 , pp. 27-34
    • Kivisäkk, P.1    Alm, G.V.2    Fredrikson, S.3    Link, H.4
  • 61
    • 0037181634 scopus 로고    scopus 로고
    • Independent comparison of interferon (INCOMIN) trial study group, every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN)
    • Durelli L., Verdun E., Barbero P., Bergui M., Versino E., Ghezzi A., et al. Independent comparison of interferon (INCOMIN) trial study group, every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002, 359:1453-1460. http://www.ncbi.nlm.nih.gov/pubmed/11988242.
    • (2002) Lancet , vol.359 , pp. 1453-1460
    • Durelli, L.1    Verdun, E.2    Barbero, P.3    Bergui, M.4    Versino, E.5    Ghezzi, A.6
  • 62
    • 33846321901 scopus 로고    scopus 로고
    • Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients
    • Gneiss C., Tripp P., Reichartseder F., Egg R., Ehling R., Lutterotti A., et al. Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients. Mult Scler 2006, 12:731-737. http://www.ncbi.nlm.nih.gov/pubmed/17263000.
    • (2006) Mult Scler , vol.12 , pp. 731-737
    • Gneiss, C.1    Tripp, P.2    Reichartseder, F.3    Egg, R.4    Ehling, R.5    Lutterotti, A.6
  • 63
    • 23644433705 scopus 로고    scopus 로고
    • Significance of neutralizing antibodies to interferon beta during treatment of multiple sclerosis: expert opinions based on the proceedings of an international consensus conference
    • Hartung H.-P., Munschauer F., Schellekens H. Significance of neutralizing antibodies to interferon beta during treatment of multiple sclerosis: expert opinions based on the proceedings of an international consensus conference. Eur J Neurol 2005, 12:588-601. http://www.ncbi.nlm.nih.gov/pubmed/16053466.
    • (2005) Eur J Neurol , vol.12 , pp. 588-601
    • Hartung, H.-P.1    Munschauer, F.2    Schellekens, H.3
  • 64
    • 20444490479 scopus 로고    scopus 로고
    • Appearance and disappearance of neutralizing antibodies during interferon-beta therapy
    • Danish Multiple Sclerosis Study Group
    • Sørensen P.S., Koch-Henriksen N., Ross C., Clemmesen K.M., Bendtzen K. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005, 65:33-39. Danish Multiple Sclerosis Study Group. http://www.ncbi.nlm.nih.gov/pubmed/15888603.
    • (2005) Neurology , vol.65 , pp. 33-39
    • Sørensen, P.S.1    Koch-Henriksen, N.2    Ross, C.3    Clemmesen, K.M.4    Bendtzen, K.5
  • 65
    • 0142121383 scopus 로고    scopus 로고
    • Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years
    • Bellomi F., Scagnolari C., Tomassini V., Gasperini C., Paolillo A., Pozzilli C., et al. Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years. J Neurol Sci 2003, 215:3-8. http://www.ncbi.nlm.nih.gov/pubmed/14568120.
    • (2003) J Neurol Sci , vol.215 , pp. 3-8
    • Bellomi, F.1    Scagnolari, C.2    Tomassini, V.3    Gasperini, C.4    Paolillo, A.5    Pozzilli, C.6
  • 66
    • 84860495711 scopus 로고    scopus 로고
    • Persistency of neutralizing antibodies depends on titer and interferon-beta preparation
    • Hegen H., Schleiser M., Gneiss C., Di Pauli F., Ehling R., Kuenz B., et al. Persistency of neutralizing antibodies depends on titer and interferon-beta preparation. Mult Scler 2012, 18:610-615. http://www.ncbi.nlm.nih.gov/pubmed/22013146.
    • (2012) Mult Scler , vol.18 , pp. 610-615
    • Hegen, H.1    Schleiser, M.2    Gneiss, C.3    Di Pauli, F.4    Ehling, R.5    Kuenz, B.6
  • 67
    • 65349183493 scopus 로고    scopus 로고
    • The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis
    • Koch-Henriksen N., Sørensen P.S., Bendtzen K., Flachs E.M. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis. Mult Scler 2009, 15:601-605. http://www.ncbi.nlm.nih.gov/pubmed/19299439.
    • (2009) Mult Scler , vol.15 , pp. 601-605
    • Koch-Henriksen, N.1    Sørensen, P.S.2    Bendtzen, K.3    Flachs, E.M.4
  • 68
    • 55649101178 scopus 로고    scopus 로고
    • The implications of immunogenicity for protein-based multiple sclerosis therapies
    • Cohen B.A., Oger J., Gagnon A., Giovannoni G. The implications of immunogenicity for protein-based multiple sclerosis therapies. J Neurol Sci 2008, 275:7-17. http://www.ncbi.nlm.nih.gov/pubmed/18822434.
    • (2008) J Neurol Sci , vol.275 , pp. 7-17
    • Cohen, B.A.1    Oger, J.2    Gagnon, A.3    Giovannoni, G.4
  • 69
    • 84857594108 scopus 로고    scopus 로고
    • Development of resistance to biologic therapies with reference to IFN-β
    • Farrell R.A., Marta M., Gaeguta A.J., Souslova V., Giovannoni G., Creeke P.I. Development of resistance to biologic therapies with reference to IFN-β. Rheumatology 2012, 51:590-599. http://www.ncbi.nlm.nih.gov/pubmed/22258390.
    • (2012) Rheumatology , vol.51 , pp. 590-599
    • Farrell, R.A.1    Marta, M.2    Gaeguta, A.J.3    Souslova, V.4    Giovannoni, G.5    Creeke, P.I.6
  • 70
    • 3242877381 scopus 로고    scopus 로고
    • Immunogenicity of interferon beta: differences among products
    • Bertolotto A., Deisenhammer F., Gallo P., Sørensen P.S. Immunogenicity of interferon beta: differences among products. J Neurol 2004, 251:II15-II24. http://www.ncbi.nlm.nih.gov/pubmed/15264108.
    • (2004) J Neurol , vol.251 , pp. II15-II24
    • Bertolotto, A.1    Deisenhammer, F.2    Gallo, P.3    Sørensen, P.S.4
  • 71
    • 84857799574 scopus 로고    scopus 로고
    • Advanced glycation end products contribute to the immunogenicity of IFN-β pharmaceuticals
    • Bozhinov A., Handzhiyski Y., Genov K., Daskalovska V., Niwa T., Ivanov I., et al. Advanced glycation end products contribute to the immunogenicity of IFN-β pharmaceuticals. J Allergy Clin Immunol 2012, 129:855-858. http://www.ncbi.nlm.nih.gov/pubmed/22154379.
    • (2012) J Allergy Clin Immunol , vol.129 , pp. 855-858
    • Bozhinov, A.1    Handzhiyski, Y.2    Genov, K.3    Daskalovska, V.4    Niwa, T.5    Ivanov, I.6
  • 72
    • 37449008267 scopus 로고    scopus 로고
    • The immunogenicity of disease-modifying therapies for multiple sclerosis: clinical implications for neurologists
    • Fox E.J., Vartanian T.K., Zamvil S.S. The immunogenicity of disease-modifying therapies for multiple sclerosis: clinical implications for neurologists. Neurologist 2007, 13:355-362. http://www.ncbi.nlm.nih.gov/pubmed/18090713.
    • (2007) Neurologist , vol.13 , pp. 355-362
    • Fox, E.J.1    Vartanian, T.K.2    Zamvil, S.S.3
  • 73
    • 84878149778 scopus 로고    scopus 로고
    • Characterization and quantitation of aggregates and particles in interferon-β products: potential links between product quality attributes and immunogenicity
    • Barnard J.G., Babcock K., Carpenter J.F. Characterization and quantitation of aggregates and particles in interferon-β products: potential links between product quality attributes and immunogenicity. J Pharm Sci 2013, 102:915-998. http://www.ncbi.nlm.nih.gov/pubmed/23233295.
    • (2013) J Pharm Sci , vol.102 , pp. 915-998
    • Barnard, J.G.1    Babcock, K.2    Carpenter, J.F.3
  • 74
    • 22044436956 scopus 로고    scopus 로고
    • Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS
    • Francis G.S., Rice G.P.A., Alsop J.C., PRISMS Study Group Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 2005, 65:48-55. http://www.ncbi.nlm.nih.gov/pubmed/16009884.
    • (2005) Neurology , vol.65 , pp. 48-55
    • Francis, G.S.1    Rice, G.P.A.2    Alsop, J.C.3
  • 75
    • 22044450811 scopus 로고    scopus 로고
    • Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study
    • Kappos L., Clanet M., Sandberg-Wollheim M., Radue E.W., Hartung H.-P., Hohlfeld R., et al. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 2005, 65:40-47. http://www.ncbi.nlm.nih.gov/pubmed/16009883.
    • (2005) Neurology , vol.65 , pp. 40-47
    • Kappos, L.1    Clanet, M.2    Sandberg-Wollheim, M.3    Radue, E.W.4    Hartung, H.-P.5    Hohlfeld, R.6
  • 76
    • 0035849494 scopus 로고    scopus 로고
    • Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results
    • Li D.K., Zhao G.J., Paty D.W., University of British Columbia MS/MRI.Analysis Research Group.The SPECTRIMS Study Group Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results. Neurology 2001, 56:1505-1513. http://www.ncbi.nlm.nih.gov/pubmed/11402107.
    • (2001) Neurology , vol.56 , pp. 1505-1513
    • Li, D.K.1    Zhao, G.J.2    Paty, D.W.3
  • 77
    • 0344809968 scopus 로고    scopus 로고
    • Evidence of interferon β-1a dose response in relapsing-remitting MS the OWIMS study
    • The Once Weekly Interferon for MS Study Group Evidence of interferon β-1a dose response in relapsing-remitting MS the OWIMS study. Neurology 1999, 53:679-686. http://www.ncbi.nlm.nih.gov/pubmed/1048902.
    • (1999) Neurology , vol.53 , pp. 679-686
  • 78
    • 0345601517 scopus 로고    scopus 로고
    • Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis
    • Prevention of relapses and disability by interferon beta-1a subcutaneously in Multiple Sclerosis (PRISMS) Study Group Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998, 352:1498-1504. http://www.ncbi.nlm.nih.gov/pubmed/9820297.
    • (1998) Lancet , vol.352 , pp. 1498-1504
  • 79
    • 0035954361 scopus 로고    scopus 로고
    • PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS
    • The Prevention of Relapses and Disability by Interferon-beta-1a Subcutaneously in Mulitple Sclerosis (PRISMS) Study Group, The University of British Columbia MS/MRI Analysis Group PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001, 56:1628-1636. http://www.ncbi.nlm.nih.gov/pubmed/11425926.
    • (2001) Neurology , vol.56 , pp. 1628-1636
  • 80
    • 36849035929 scopus 로고    scopus 로고
    • Full results of the evidence of interferon dose-response - European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon β-1a for relapsing multiple sclerosis
    • Schwid S.R., Panitch H.S. full results of the evidence of interferon dose-response - European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon β-1a for relapsing multiple sclerosis. Clin Ther 2007, 29:2031-2048. http://www.ncbi.nlm.nih.gov/pubmed/18035202.
    • (2007) Clin Ther , vol.29 , pp. 2031-2048
    • Schwid, S.R.1    Panitch, H.S.2
  • 81
    • 68249162126 scopus 로고    scopus 로고
    • Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity
    • Hesse D., Sellebjerg F., Sørensen P.S. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity. Neurology 2009, 73:372-377. http://www.ncbi.nlm.nih.gov/pubmed/19652141.
    • (2009) Neurology , vol.73 , pp. 372-377
    • Hesse, D.1    Sellebjerg, F.2    Sørensen, P.S.3
  • 82
    • 0037465461 scopus 로고    scopus 로고
    • Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients
    • Bertolotto A., Gilli F., Sala A., Capobianco M., Malucchi S., Milano E., et al. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. Neurology 2003, 60:634-639. http://www.ncbi.nlm.nih.gov/pubmed/12601105.
    • (2003) Neurology , vol.60 , pp. 634-639
    • Bertolotto, A.1    Gilli, F.2    Sala, A.3    Capobianco, M.4    Malucchi, S.5    Milano, E.6
  • 83
    • 70449449076 scopus 로고    scopus 로고
    • Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study
    • INSIGHT Investigators
    • Pachner A.R., Warth J.D., Pace A., Goelz S. Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study. Neurology 2009, 73:1493-1500. INSIGHT Investigators. http://www.ncbi.nlm.nih.gov/pubmed/19884577.
    • (2009) Neurology , vol.73 , pp. 1493-1500
    • Pachner, A.R.1    Warth, J.D.2    Pace, A.3    Goelz, S.4
  • 84
    • 34249329604 scopus 로고    scopus 로고
    • Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies
    • Scagnolari C., Duda P., Bagnato F., De Vito G., Alberelli A., Lavolpe V., et al. Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies. J Neurol 2007, 254:597-604. http://www.ncbi.nlm.nih.gov/pubmed/17420930.
    • (2007) J Neurol , vol.254 , pp. 597-604
    • Scagnolari, C.1    Duda, P.2    Bagnato, F.3    De Vito, G.4    Alberelli, A.5    Lavolpe, V.6
  • 85
    • 0005489101 scopus 로고    scopus 로고
    • Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years
    • The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996, 47:889-894. http://www.ncbi.nlm.nih.gov/pubmed/8857714.
    • (1996) Neurology , vol.47 , pp. 889-894
  • 86
    • 10744225329 scopus 로고    scopus 로고
    • Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis
    • Sørensen P.S., Ross C., Clemmesen K.M., Bendtzen K., Frederiksen J.L., Jensen K., et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003, 362:1184-1191. http://www.ncbi.nlm.nih.gov/pubmed/14568740.
    • (2003) Lancet , vol.362 , pp. 1184-1191
    • Sørensen, P.S.1    Ross, C.2    Clemmesen, K.M.3    Bendtzen, K.4    Frederiksen, J.L.5    Jensen, K.6
  • 87
    • 0032494792 scopus 로고    scopus 로고
    • Placebo-controlled multicentre randomised trial of interferon [beta]-1b in treatment of secondary progressive multiple sclerosis
    • European study group on interferon beta-1b in secondary progressive MS Placebo-controlled multicentre randomised trial of interferon [beta]-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998, 352:1491-1497. http://www.ncbi.nlm.nih.gov/pubmed/9820296.
    • (1998) Lancet , vol.352 , pp. 1491-1497
  • 88
    • 1642277003 scopus 로고    scopus 로고
    • The clinical impact of interferon beta antibodies in relapsing-remitting MS
    • Perini P., Calabrese M., Biasi G., Gallo P. The clinical impact of interferon beta antibodies in relapsing-remitting MS. J Neurol 2004, 251:305-309. http://www.ncbi.nlm.nih.gov/pubmed/15015010.
    • (2004) J Neurol , vol.251 , pp. 305-309
    • Perini, P.1    Calabrese, M.2    Biasi, G.3    Gallo, P.4
  • 89
    • 84878839989 scopus 로고    scopus 로고
    • The impact of neutralizing antibodies on the risk of disease worsening in interferon β-treated relapsing multiple sclerosis: a 5 year post-marketing study
    • Paolicelli D., D'Onghia M., Pellegrini F., Direnzo V., Iaffaldano P., Lavolpe V., et al. The impact of neutralizing antibodies on the risk of disease worsening in interferon β-treated relapsing multiple sclerosis: a 5 year post-marketing study. J Neurol 2013, 260:1562-1568. http://www.ncbi.nlm.nih.gov/pubmed/23417273.
    • (2013) J Neurol , vol.260 , pp. 1562-1568
    • Paolicelli, D.1    D'Onghia, M.2    Pellegrini, F.3    Direnzo, V.4    Iaffaldano, P.5    Lavolpe, V.6
  • 90
    • 34147167957 scopus 로고    scopus 로고
    • Neutralizing antibodies to interferon-1b are not associated with disease worsening in multiple sclerosis
    • Goodin D.S., Hurwitz B., Noronha A. Neutralizing antibodies to interferon-1b are not associated with disease worsening in multiple sclerosis. J Int Med Res 2007, 35:173-187. http://www.ncbi.nlm.nih.gov/pubmed/17542405.
    • (2007) J Int Med Res , vol.35 , pp. 173-187
    • Goodin, D.S.1    Hurwitz, B.2    Noronha, A.3
  • 91
    • 48349102333 scopus 로고    scopus 로고
    • Important sources of variability in clinical studies of neutralizing antibodies against interferon beta
    • Hurwitz B.J. Important sources of variability in clinical studies of neutralizing antibodies against interferon beta. J Neurol Sci 2008, 272:8-19. http://www.ncbi.nlm.nih.gov/pubmed/18620708.
    • (2008) J Neurol Sci , vol.272 , pp. 8-19
    • Hurwitz, B.J.1
  • 92
    • 34347367354 scopus 로고
    • WHO Expert Committee on Biological Standardization. Forty-fifth report
    • World Health Organization WHO Expert Committee on Biological Standardization. Forty-fifth report. World Health Organization Technical Rep Ser 1995, 858:1-101. http://www.ncbi.nlm.nih.gov/pubmed/8650946.
    • (1995) World Health Organization Technical Rep Ser , vol.858 , pp. 1-101
  • 93
    • 0034798067 scopus 로고    scopus 로고
    • The neutralization of interferons by antibody. I. Quantitative and theoretical analyses of the neutralization reaction in different bioassay systems
    • Grossberg S.E., Kawade Y., Kohase M., Yokoyama H., Finter N. The neutralization of interferons by antibody. I. Quantitative and theoretical analyses of the neutralization reaction in different bioassay systems. J Interferon Cytokine Res 2001, 21:729-742. http://www.ncbi.nlm.nih.gov/pubmed/11576467.
    • (2001) J Interferon Cytokine Res , vol.21 , pp. 729-742
    • Grossberg, S.E.1    Kawade, Y.2    Kohase, M.3    Yokoyama, H.4    Finter, N.5
  • 94
    • 0034796419 scopus 로고    scopus 로고
    • The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit
    • Grossberg S.E., Kawade Y., Kohase M., Klein J.P. The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit. J Interferon Cytokine Res 2001, 21:743-755. http://www.ncbi.nlm.nih.gov/pubmed/11576468.
    • (2001) J Interferon Cytokine Res , vol.21 , pp. 743-755
    • Grossberg, S.E.1    Kawade, Y.2    Kohase, M.3    Klein, J.P.4
  • 95
    • 84881550245 scopus 로고    scopus 로고
    • Use of a standardized MxA protein measurement-based assay for validation of assays for the assessment of neutralizing antibodies against interferon-β
    • Wadhwa M., Subramanyam M., Goelz S., Goyal J., Jethwa V., Jones W., et al. Use of a standardized MxA protein measurement-based assay for validation of assays for the assessment of neutralizing antibodies against interferon-β. J Interferon Cytokine Res 2013, 33:660-671. http://www.ncbi.nlm.nih.gov/pubmed/23848523.
    • (2013) J Interferon Cytokine Res , vol.33 , pp. 660-671
    • Wadhwa, M.1    Subramanyam, M.2    Goelz, S.3    Goyal, J.4    Jethwa, V.5    Jones, W.6
  • 97
    • 58149149644 scopus 로고    scopus 로고
    • Neutralizing and binding antibodies to interferon beta in patients with multiple sclerosis: a comparison of assay results from three Italian centres
    • Bellomi F., Bramanti P., Trojano M., Scagnolari C., Muto A., Sessa E., et al. Neutralizing and binding antibodies to interferon beta in patients with multiple sclerosis: a comparison of assay results from three Italian centres. J Immunoassay Immunochem 2009, 30:40-50. http://www.ncbi.nlm.nih.gov/pubmed/19117201.
    • (2009) J Immunoassay Immunochem , vol.30 , pp. 40-50
    • Bellomi, F.1    Bramanti, P.2    Trojano, M.3    Scagnolari, C.4    Muto, A.5    Sessa, E.6
  • 98
    • 84862214154 scopus 로고    scopus 로고
    • Variability in detection and quantification of interferon β-1b-induced neutralizing antibodies
    • Hartung H.-P., Kieseier B., Goodin D.S., Arnason B.G.W., Comi G., Cook S., et al. Variability in detection and quantification of interferon β-1b-induced neutralizing antibodies. J Neuroinflamm 2012, 9:129. http://www.ncbi.nlm.nih.gov/pubmed/22703536.
    • (2012) J Neuroinflamm , vol.9 , pp. 129
    • Hartung, H.-P.1    Kieseier, B.2    Goodin, D.S.3    Arnason, B.G.W.4    Comi, G.5    Cook, S.6
  • 99
    • 27744509228 scopus 로고    scopus 로고
    • Guidelines on use of anti-IFN-B antibody measurements in multiple sclerosis: report of an EFNS task force on IFN-B antibodies in multiple sclerosis
    • Sørensen P.S., Deisenhammer F., Duda P., Hohlfeld R., Myhr K.-M., Palace J., et al. Guidelines on use of anti-IFN-B antibody measurements in multiple sclerosis: report of an EFNS task force on IFN-B antibodies in multiple sclerosis. Eur J Neurol 2005, 12:817-827. http://www.ncbi.nlm.nih.gov/pubmed/16241970.
    • (2005) Eur J Neurol , vol.12 , pp. 817-827
    • Sørensen, P.S.1    Deisenhammer, F.2    Duda, P.3    Hohlfeld, R.4    Myhr, K.-M.5    Palace, J.6
  • 100
    • 0242333124 scopus 로고    scopus 로고
    • MxA gene expression analysis as an interferon-beta bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity
    • Pachner A., Narayan K., Price N., Hurd M., Dail D. MxA gene expression analysis as an interferon-beta bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity. Mol Diagn 2003, 7:17-25. http://www.ncbi.nlm.nih.gov/pubmed/14529316.
    • (2003) Mol Diagn , vol.7 , pp. 17-25
    • Pachner, A.1    Narayan, K.2    Price, N.3    Hurd, M.4    Dail, D.5
  • 101
    • 33947322141 scopus 로고    scopus 로고
    • Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta
    • Bertolotto A., Sala A., Caldano M., Capobianco M., Malucchi S., Marnetto F., et al. Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta. J Immunol Methods 2007, 321:19-31. http://www.ncbi.nlm.nih.gov/pubmed/17335844.
    • (2007) J Immunol Methods , vol.321 , pp. 19-31
    • Bertolotto, A.1    Sala, A.2    Caldano, M.3    Capobianco, M.4    Malucchi, S.5    Marnetto, F.6
  • 102
    • 59049104823 scopus 로고    scopus 로고
    • Measurement of neutralising antibodies to type I interferons by gene expression assays specific for type 1 interferon-inducible 6-16 mRNA
    • Moore M., Meager A., Wadhwa M., Burns C. Measurement of neutralising antibodies to type I interferons by gene expression assays specific for type 1 interferon-inducible 6-16 mRNA. J Pharm Biomed Anal 2009, 49:534-539. http://www.ncbi.nlm.nih.gov/pubmed/19097723.
    • (2009) J Pharm Biomed Anal , vol.49 , pp. 534-539
    • Moore, M.1    Meager, A.2    Wadhwa, M.3    Burns, C.4
  • 103
    • 80052008848 scopus 로고    scopus 로고
    • Search for specific biomarkers of IFNβ bioactivity in patients with multiple sclerosis
    • Malhotra S., Bustamante M.F., Pérez-Miralles F., Rio J., Ruiz de Villa M.C., Vegas E., et al. Search for specific biomarkers of IFNβ bioactivity in patients with multiple sclerosis. PLOS ONE 2011, 6:e23634. http://www.ncbi.nlm.nih.gov/pubmed/21886806, 10.1371/journal.pone.0023634.
    • (2011) PLOS ONE , vol.6 , pp. e23634
    • Malhotra, S.1    Bustamante, M.F.2    Pérez-Miralles, F.3    Rio, J.4    Ruiz de Villa, M.C.5    Vegas, E.6
  • 104
    • 72749127602 scopus 로고    scopus 로고
    • Influence of interferon-beta therapy switching on neutralizing antibody titres: results from the Austrian Switch Study
    • Gneiss C., Koudouovoh-Tripp P.-M., Ropele S., Gotwald T., Ehling R., Lutterotti A., et al. Influence of interferon-beta therapy switching on neutralizing antibody titres: results from the Austrian Switch Study. Mult Scler 2009, 15:1481-1488. http://www.ncbi.nlm.nih.gov/pubmed/19965519.
    • (2009) Mult Scler , vol.15 , pp. 1481-1488
    • Gneiss, C.1    Koudouovoh-Tripp, P.-M.2    Ropele, S.3    Gotwald, T.4    Ehling, R.5    Lutterotti, A.6
  • 105
    • 35148871325 scopus 로고    scopus 로고
    • Re: neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the therapeutics and technology assessment subcommittee of the american academy of neurology
    • author reply 1553
    • Sørensen P.S., Bertolotto A. Re: neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the therapeutics and technology assessment subcommittee of the american academy of neurology. Neurology 2007, 69:1552. author reply 1553. http://www.ncbi.nlm.nih.gov/pubmed/17923618.
    • (2007) Neurology , vol.69 , pp. 1552
    • Sørensen, P.S.1    Bertolotto, A.2
  • 106
    • 77953454473 scopus 로고    scopus 로고
    • Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis
    • Polman C.H., Bertolotto A., Deisenhammer F., Giovannoni G., Hartung H.-P., Hemmer B., et al. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol 2010, 9(7):740-750. http://www.ncbi.nlm.nih.gov/pubmed/20610349.
    • (2010) Lancet Neurol , vol.9 , Issue.7 , pp. 740-750
    • Polman, C.H.1    Bertolotto, A.2    Deisenhammer, F.3    Giovannoni, G.4    Hartung, H.-P.5    Hemmer, B.6
  • 107
    • 48349093740 scopus 로고    scopus 로고
    • HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis
    • Hoffmann S., Cepok S., Grummel V., Lehmann-Horn K., Hackermüller J., Stadler P.F., et al. HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis. Am J Hum Genet 2008, 83:219-227. http://www.ncbi.nlm.nih.gov/pubmed/18656179.
    • (2008) Am J Hum Genet , vol.83 , pp. 219-227
    • Hoffmann, S.1    Cepok, S.2    Grummel, V.3    Lehmann-Horn, K.4    Hackermüller, J.5    Stadler, P.F.6
  • 108
    • 85027958957 scopus 로고    scopus 로고
    • Single-nucleotide polymorphisms in HLA-and non-hla genes associated with the development of antibodies to interferon-β therapy in multiple sclerosis patients
    • Weber F., Cepok S., Wolf C., Berthele A., Uhr M., Bettecken T.H., et al. Single-nucleotide polymorphisms in HLA-and non-hla genes associated with the development of antibodies to interferon-β therapy in multiple sclerosis patients. Pharmacogenomics J 2012, 12:238-245. http://www.ncbi.nlm.nih.gov/pubmed/21502966.
    • (2012) Pharmacogenomics J , vol.12 , pp. 238-245
    • Weber, F.1    Cepok, S.2    Wolf, C.3    Berthele, A.4    Uhr, M.5    Bettecken, T.H.6
  • 109
    • 79953847674 scopus 로고    scopus 로고
    • Influence of the HLA-DRB1 genotype on antibody development to interferon beta in multiple sclerosis
    • Buck D., Cepok S., Hoffmann S., Grummel V., Jochim A., Berthele A., et al. Influence of the HLA-DRB1 genotype on antibody development to interferon beta in multiple sclerosis. Arch Neurol 2011, 68:480-487. http://www.ncbi.nlm.nih.gov/pubmed/21482927.
    • (2011) Arch Neurol , vol.68 , pp. 480-487
    • Buck, D.1    Cepok, S.2    Hoffmann, S.3    Grummel, V.4    Jochim, A.5    Berthele, A.6
  • 110
    • 77955164022 scopus 로고    scopus 로고
    • Polymorphisms of innate pattern recognition receptors, response to interferon-beta and development of neutralizing antibodies in multiple sclerosis patients
    • Enevold C., Oturai A.B., Sørensen P.S., Ryder L.P., Koch-Henriksen N., Bendtzen K. Polymorphisms of innate pattern recognition receptors, response to interferon-beta and development of neutralizing antibodies in multiple sclerosis patients. Mult Scler 2010, 16:942-949. http://www.ncbi.nlm.nih.gov/pubmed/20595247.
    • (2010) Mult Scler , vol.16 , pp. 942-949
    • Enevold, C.1    Oturai, A.B.2    Sørensen, P.S.3    Ryder, L.P.4    Koch-Henriksen, N.5    Bendtzen, K.6
  • 111
    • 28444474235 scopus 로고    scopus 로고
    • Pharmacogenetics of autoimmune diseases: research issues in the case of multiple sclerosis and the role of IFN-beta
    • Macciardi F., Martinelli Boneschi F., Cohen D. Pharmacogenetics of autoimmune diseases: research issues in the case of multiple sclerosis and the role of IFN-beta. J Autoimmun 2005, 25(Suppl.):1-5. http://www.ncbi.nlm.nih.gov/pubmed/16311019.
    • (2005) J Autoimmun , vol.25 , pp. 1-5
    • Macciardi, F.1    Martinelli Boneschi, F.2    Cohen, D.3
  • 112
    • 84926517290 scopus 로고    scopus 로고
    • Long-term efficacy and safety of Fingolimod in Japanese patients with relapsing multiple sclerosis (MS): 3-year results from a phase 2 extension study
    • [Poster (P-56) presented at the 6th PACTRIMS Congress, 6-8 Nov. 2013, Kyoto, Japan]
    • Kira J., Itoyama Y., Kikuchi S., Hao Q., Kurosawa T., Ueda K., et al. Long-term efficacy and safety of Fingolimod in Japanese patients with relapsing multiple sclerosis (MS): 3-year results from a phase 2 extension study. Mult Scler J 2014, 20(7):9282. [Poster (P-56) presented at the 6th PACTRIMS Congress, 6-8 Nov. 2013, Kyoto, Japan].
    • (2014) Mult Scler J , vol.20 , Issue.7 , pp. 9282
    • Kira, J.1    Itoyama, Y.2    Kikuchi, S.3    Hao, Q.4    Kurosawa, T.5    Ueda, K.6
  • 113
    • 84926520880 scopus 로고    scopus 로고
    • 3-Year follow-up of oral BG-12 (dimethyl fumerate) for relapsing-remitting multiple sclerosis (RRMS): integrated MRI outcomes from the DEFINE, CONFIRM, and ENDORSE studies
    • [Poster (P-66) presented at the 6th PACTRIMS meeting, 6-8 Nov. 2013, Kyoto, Japan]
    • Miller D.H., Fox R.J., Gold R., Havrdova E., Kappos K., Yousry T., et al. 3-Year follow-up of oral BG-12 (dimethyl fumerate) for relapsing-remitting multiple sclerosis (RRMS): integrated MRI outcomes from the DEFINE, CONFIRM, and ENDORSE studies. Mult Scler J 2014, 20(7):932. [Poster (P-66) presented at the 6th PACTRIMS meeting, 6-8 Nov. 2013, Kyoto, Japan].
    • (2014) Mult Scler J , vol.20 , Issue.7 , pp. 932
    • Miller, D.H.1    Fox, R.J.2    Gold, R.3    Havrdova, E.4    Kappos, K.5    Yousry, T.6
  • 114
    • 84926520880 scopus 로고    scopus 로고
    • 3-Year follow-up of oral BG-12 (Dimethyl Fumerate) for relapsing-remitting multiple sclerosis (RRMS): integrated clinical outcomes from the DEFINE, CONFIRM, and ENDORSE studies
    • [Poster (P-67) presented at the 6th PACTRIMS meeting, 6-8 Nov. 2013, Kyoto, Japan]
    • Gold R., Phillips J.T., Bar-Or A., Hutchinson M., Kappos L., Rana J., et al. 3-Year follow-up of oral BG-12 (Dimethyl Fumerate) for relapsing-remitting multiple sclerosis (RRMS): integrated clinical outcomes from the DEFINE, CONFIRM, and ENDORSE studies. Mult Scler J 2014, 20(7):932. [Poster (P-67) presented at the 6th PACTRIMS meeting, 6-8 Nov. 2013, Kyoto, Japan].
    • (2014) Mult Scler J , vol.20 , Issue.7 , pp. 932
    • Gold, R.1    Phillips, J.T.2    Bar-Or, A.3    Hutchinson, M.4    Kappos, L.5    Rana, J.6
  • 115
    • 84926525699 scopus 로고    scopus 로고
    • Three placebo-controlled teriflunomide studies: pooled safety data
    • [Poster (P-70) presented at the 6th PACTRIMS meeting, 6-8 Nov. 2013, Kyoto, Japan]
    • Leist T.P., Freedman M.S., Kappos L., Olsson T.P., Miller A.E., Wolinsky J.S., et al. Three placebo-controlled teriflunomide studies: pooled safety data. Mult Scler J 2014, 20(7):933. [Poster (P-70) presented at the 6th PACTRIMS meeting, 6-8 Nov. 2013, Kyoto, Japan].
    • (2014) Mult Scler J , vol.20 , Issue.7 , pp. 933
    • Leist, T.P.1    Freedman, M.S.2    Kappos, L.3    Olsson, T.P.4    Miller, A.E.5    Wolinsky, J.S.6
  • 116
    • 84883750369 scopus 로고    scopus 로고
    • Roles of the ubiquitin peptidase USP18 in multiple sclerosis and the response to interferon-β treatment
    • Malhotra S., Morcillo-Suárez C., Nurtdinov R., Rio J., Sarro E., Moreno M., et al. Roles of the ubiquitin peptidase USP18 in multiple sclerosis and the response to interferon-β treatment. Eur J Neurol 2013, 20:1390-1397. http://www.ncbi.nlm.nih.gov/pubmed/23700969.
    • (2013) Eur J Neurol , vol.20 , pp. 1390-1397
    • Malhotra, S.1    Morcillo-Suárez, C.2    Nurtdinov, R.3    Rio, J.4    Sarro, E.5    Moreno, M.6
  • 117
    • 84870034810 scopus 로고    scopus 로고
    • Allelic combinations of immune-response genes as possible composite markers of IFN-beta efficacy in multiple sclerosis patients
    • Kulakova O.G., Tsareva E.Y., Boyko A.N., Shchur S.G., Gusev E.I., Lvovs D., et al. Allelic combinations of immune-response genes as possible composite markers of IFN-beta efficacy in multiple sclerosis patients. Pharmacogenomics 2012, 13:1689-1700. http://www.ncbi.nlm.nih.gov/pubmed/23171334.
    • (2012) Pharmacogenomics , vol.13 , pp. 1689-1700
    • Kulakova, O.G.1    Tsareva, E.Y.2    Boyko, A.N.3    Shchur, S.G.4    Gusev, E.I.5    Lvovs, D.6
  • 118
    • 80053394440 scopus 로고    scopus 로고
    • CD46 in a Spanish cohort of multiple sclerosis patients: genetics, mRNA expression and response to interferon-beta treatment
    • Alvarez-Lafuente R., Blanco-Kelly F., Garcia-Montojo M., Martínez A., De Las Heras V., Dominguez-Mozo M.I., et al. CD46 in a Spanish cohort of multiple sclerosis patients: genetics, mRNA expression and response to interferon-beta treatment. Mult Scler 2011, 17:513-520. http://www.ncbi.nlm.nih.gov/pubmed/21177319.
    • (2011) Mult Scler , vol.17 , pp. 513-520
    • Alvarez-Lafuente, R.1    Blanco-Kelly, F.2    Garcia-Montojo, M.3    Martínez, A.4    De Las Heras, V.5    Dominguez-Mozo, M.I.6
  • 119
    • 33644961793 scopus 로고    scopus 로고
    • An IFNG polymorphism is associated with interferon-beta response in Spanish MS patients
    • Martínez A., de las Heras V., Mas Fontao A., Bartolomé M., de la Concha E.G., Urcelay E., et al. An IFNG polymorphism is associated with interferon-beta response in Spanish MS patients. J Neuroimmunol 2006, 173:196-199. http://www.ncbi.nlm.nih.gov/pubmed/16430971.
    • (2006) J Neuroimmunol , vol.173 , pp. 196-199
    • Martínez, A.1    de las Heras, V.2    Mas Fontao, A.3    Bartolomé, M.4    de la Concha, E.G.5    Urcelay, E.6

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.